Drug Profile


Alternative Names: 18F-FMAU; 2'-fluoro-5-methylarabinosyluracil; FM-ara-U; NSC 678516

Latest Information Update: 18 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Bristol-Myers Squibb; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Antivirals; Arabinonucleosides; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Herpes simplex virus infections; Solid tumours

Most Recent Events

  • 18 Jul 2011 Discontinued - Preclinical for Herpes simplex virus infections in USA (unspecified route)
  • 18 Jul 2011 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
  • 30 May 1995 Preclinical for Herpes simplex virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top